Lesley-Ann Sutton
Overview
Explore the profile of Lesley-Ann Sutton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagerstrand D, Oder B, Cortese D, Qu Y, Binzer-Panchal A, Osterholm C, et al.
Leukemia
. 2024 Sep;
38(11):2429-2442.
PMID: 39261602
SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 SF3B1 and 17 SF3B1...
2.
Bonfiglio S, Sutton L, Ljungstrom V, Capasso A, Pandzic T, Westrom S, et al.
Blood Adv
. 2023 Jan;
7(12):2794-2806.
PMID: 36696464
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance...
3.
Mansouri L, Thorvaldsdottir B, Sutton L, Karakatsoulis G, Meggendorfer M, Parker H, et al.
Leukemia
. 2023 Jan;
37(2):504.
PMID: 36635392
No abstract available.
4.
Mansouri L, Thorvaldsdottir B, Sutton L, Karakatsoulis G, Meggendorfer M, Parker H, et al.
Leukemia
. 2022 Dec;
37(2):339-347.
PMID: 36566271
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM)...
5.
Chiodin G, Drennan S, Martino E, Ondrisova L, Henderson I, Del Rio L, et al.
Blood Adv
. 2022 May;
6(18):5494-5504.
PMID: 35640238
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM) levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within these low levels, CLL with relatively high sIgM...
6.
7.
Stewart J, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G, et al.
Blood Adv
. 2021 Aug;
5(16):3188-3198.
PMID: 34424321
Current diagnostic standards for lymphoproliferative disorders include multiple tests for detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements, translocations, copy-number alterations (CNAs), and somatic mutations. The EuroClonality-NGS DNA...
8.
Gemenetzi K, Psomopoulos F, Carriles A, Gounari M, Minici C, Plevova K, et al.
Blood
. 2020 Oct;
137(14):1895-1904.
PMID: 33036024
Chronic lymphocytic leukemia (CLL) major stereotyped subset 2 (IGHV3-21/IGLV3-21, ∼2.5% of all cases of CLL) is an aggressive disease variant, irrespective of the somatic hypermutation (SHM) status of the clonotypic...
9.
Ioannou N, Hagner P, Stokes M, Gandhi A, Apollonio B, Fanous M, et al.
Blood
. 2020 Oct;
137(2):216-231.
PMID: 33024998
Cancer treatment has been transformed by checkpoint blockade therapies, with the highest anti-tumor activity of anti-programmed death 1 (PD-1) antibody therapy seen in Hodgkin lymphoma. Disappointingly, response rates have been...
10.
Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, et al.
Blood
. 2020 Sep;
137(10):1365-1376.
PMID: 32992344
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent...